Core Insights - Hologic (HOLX) is expected to report quarterly earnings of $1.09 per share, reflecting a year-over-year increase of 5.8% and revenues of $1.07 billion, up 4.9% from the previous year [1] - Analysts have revised their consensus EPS estimate upward by 0.6% over the past 30 days, indicating a collective reassessment of projections [1][2] Revenue Projections - Analysts estimate 'Revenues- GYN surgical' will reach $180.97 million, indicating a year-over-year change of +8.8% [4] - 'Revenues- Diagnostics- Molecular diagnostics' are projected at $354.66 million, with a year-over-year change of +4% [4] - The consensus for 'Revenues- Diagnostics- Blood screening' stands at $4.77 million, reflecting a year-over-year change of +16.3% [4] - 'Revenues- Breast health- Breast imaging' is expected to be $294.22 million, showing a change of +4.5% from the prior year [5] - 'Revenues- Total Diagnostics' are forecasted at $479.84 million, indicating a change of +2% from the previous year [5] - 'Revenues- Skeletal health' is projected to reach $20.13 million, with a year-over-year change of +27.4% [5] - 'Revenues- Diagnostics- Cytology and perinatal' is estimated at $120.41 million, reflecting a change of -4% from the prior year [6] - 'Revenues- Total Breast health' is expected to be $392.22 million, indicating a year-over-year change of +6.3% [6] - 'Revenues- Breast health- Interventional breast solutions' is projected at $98.00 million, with a change of +12% from the previous year [7] - 'Revenues- Service and other' are expected to reach $212.72 million, indicating a change of +4.3% from the prior year [7] - The consensus for 'Revenues- Product' is $860.93 million, reflecting a change of +5.3% from the previous year [8] Market Performance - Hologic shares have experienced a change of +0.7% in the past month, compared to a +0.2% move of the Zacks S&P 500 composite [8] - Hologic holds a Zacks Rank 3 (Hold), suggesting it is expected to mirror overall market performance in the near future [8]